Ali Alahmari

Ali Alahmari

Auto-generated profile, based on publicly available information

Ali Alahmari

Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
AKAdetola A Kassim
Adetola A Kassim
JFJosu de la Fuente
Josu de la Fuente
ENErfan Nur
Erfan Nur
KWKarina L. Wilkerson
Karina L. Wilkerson
AAAli D. Alahmari
Ali D. Alahmari
MDMichael DeBaun
Michael DeBaun
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

25 January 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
MAManar Aleid
Manar Aleid
RFRiad El Fakih
Riad El Fakih
AHAmr Hanbali
Amr Hanbali
FAFeras Alfraih
Feras Alfraih
HAHaya Alothaimeen
Haya Alothaimeen
MAMansour Alfayez
Mansour Alfayez

30 May 2026 in Blood Global Hematology
Verified
Journal Article
Open access
CLChokri Ben Lamine
Chokri Ben Lamine
NANourah Alzaidy
Nourah Alzaidy
MSMohamed Isam Sharif
Mohamed Isam Sharif
AHAmal Hejab
Amal Hejab
MSMarwan Shaheen
Marwan Shaheen
NCNaeem A. Chaudhri
Naeem A. Chaudhri

28 April 2026 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
RAReem Alasbali
Reem Alasbali
MAMohsen Alzahrani
Mohsen Alzahrani
KWKarina Wilkerson
Karina Wilkerson
PAPhavina Akhom
Phavina Akhom
FAFahad Alotaibi
Fahad Alotaibi
AAAli AlAhmari
Ali AlAhmari